Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $1.59 in the prior trading day, Sutro Biopharma Inc (NASDAQ: STRO) closed at $1.43, down -9.75%. In other words, the price has decreased by -$9.75 from its previous closing price. On the day, 1.4 million shares were traded.
Ratios:
Our goal is to gain a better understanding of STRO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.09 and its Current Ratio is at 3.09. In the meantime, Its Debt-to-Equity ratio is 1.77 whereas as Long-Term Debt/Eq ratio is at 1.70.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on May 08, 2024, initiated with a Buy rating and assigned the stock a target price of $12.
On November 09, 2023, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $12.
On October 06, 2023, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $10.Oppenheimer initiated its Outperform rating on October 06, 2023, with a $10 target price.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.74 while its Price-to-Book (P/B) ratio in mrq is 1.06.
Stock Price History:
Over the past 52 weeks, STRO has reached a high of $6.13, while it has fallen to a 52-week low of $1.50. The 50-Day Moving Average of the stock is -22.91%, while the 200-Day Moving Average is calculated to be -55.26%.
Shares Statistics:
A total of 82.40M shares are outstanding, with a floating share count of 74.61M. Insiders hold about 9.52% of the company’s shares, while institutions hold 68.90% stake in the company.
Earnings Estimates
As of right now, 2.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.92, with high estimates of -$0.92 and low estimates of -$0.92.
Analysts are recommending an EPS of between -$2.92 and -$3.22 for the fiscal current year, implying an average EPS of -$3.07. EPS for the following year is -$3.41, with 2.0 analysts recommending between -$2.93 and -$3.9.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for STRO’s current fiscal year. The highest revenue estimate was $72.01M, while the lowest revenue estimate was $47.2M, resulting in an average revenue estimate of $59.2M. In the same quarter a year ago, actual revenue was $153.73M
